Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01492972 | Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer | recruiting | Phase 3 | 192 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | recruiting | Phase 3 | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | recruiting | Phase 3 | 1,210 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | recruiting | Phase 2 / Phase 3 | 131 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | recruiting | Phase 3 | 360 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05856773 | Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy(COMPRO) | recruiting | Phase 3 | 276 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT05987241 | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | recruiting | Phase 2 / Phase 3 | 992 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | recruiting | Phase 3 | 3,680 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | recruiting | Phase 3 | 306 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | recruiting | Phase 3 | 320 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06627712 | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | recruiting | Phase 3 | 318 | West China HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06637150 | Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer | recruiting | Phase 3 | 1,388 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301) | recruiting | Phase 3 | 590 | Revolution Medicines, Inc.INDUSTRY | 19 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 3 | 720 | Arcus Biosciences, Inc.INDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | recruiting | Phase 3 | 255 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07265674 | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer(Beacon-BTC) | recruiting | Phase 3 | 480 | J-Pharma Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)(DURGA-4) | recruiting | Phase 3 | 508 | AstraZenecaINDUSTRY | 15 | Sep 29, 2026 | clinicaltrials |
| NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | recruiting | Phase 3 | 670 | Boehringer IngelheimINDUSTRY | 42 | Sep 29, 2026 | clinicaltrials |
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)(VENP-A-QUI) | recruiting | Phase 3 | 376 | PETHEMA FoundationOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | recruiting | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | recruiting | Phase 3 | 247 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | recruiting | Phase 3 | 416 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04789694 | Prehabilitation in Gynaecological Cancer Patients(PHOCUS) | recruiting | Phase 3 | 64 | Charles University, Czech RepublicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | recruiting | Phase 3 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 28, 2026 | clinicaltrials |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | recruiting | Phase 3 | 300 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT06919965 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3) | recruiting | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy(ARCH) | recruiting | Phase 3 | 390 | ETOP IBCSG Partners FoundationNETWORK | 9 | Sep 28, 2026 | clinicaltrials |
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06973187 | A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07174427 | Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma | recruiting | Phase 3 | 5 | Takara Bio Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | recruiting | Phase 3 | 675 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Sep 28, 2026 | clinicaltrials |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)(AB02) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 550 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | recruiting | Phase 3 | 1,978 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07432178 | CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon) | recruiting | Phase 3 | 2,288 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07498907 | Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma(LUXUS41) | recruiting | Phase 3 | 192 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials